新疆百花村医药集团股份有限公司 证券代码：600721 证券简称：百花医药 公告编号：2026-002 新疆百花村医药集团股份有限公司 股票交易异常波动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 新疆百花村医药集团股份有限公司（以下简称"公司"）股票在连续三 个交易日内日收盘价格跌幅偏离值累计达到 20%。根据《上海证券交易所股票上 市规则》（以下简称"上市规则"）的有关规定，属于股票交易异常波动。 经公司自查并向控股股东、实控人核实，公司控股股东、实际控制人筹 划控制权变更事项已终止，详见前期公告，除公司已披露公告之外，不存在应披 露而未披露的重大信息。 截止目前，公司生产经营情况正常。 一、股票交易异常波动的具体情况 公司股票于 2026 年 1 月 7 日、2026 年 1 月 8 日、2026 年 1 月 9 日连续三个 交易日内日收盘价格跌幅偏离值累计达到 20%，根据《上市规则》的有关规定， 属于股票交易异常波动。 二、公司关注并核实的相关情况 （一）生产经营情况 经公司自查，截至目前，公 ...

2025年10月28日公司发布的三季报数据显示，前三季度公司共实现营业收入2.99亿元，同比增长 2.74%，实现净利润3267.42万元，同比增长36.41%。（数据宝） 百花医药(600721)今日跌停，全天换手率6.85%，成交额2.62亿元，振幅1.81%。龙虎榜数据显示，营业 部席位合计净卖出1864.45万元。 上交所公开信息显示，当日该股因日跌幅偏离值达-9.91%上榜，营业部席位合计净卖出1864.45万元。 证券时报·数据宝统计显示，上榜的前五大买卖营业部合计成交5306.91万元，其中，买入成交额为 1721.23万元，卖出成交额为3585.68万元，合计净卖出1864.45万元。 具体来看，今日上榜营业部中，第一大买入营业部为中山证券有限责任公司广州琶洲大道东证券营业 部，买入金额为495.90万元，第一大卖出营业部为中国银河证券股份有限公司青田龙津路证券营业部， 卖出金额为1018.98万元。 近半年该股累计上榜龙虎榜5次，上榜次日股价平均跌2.37%，上榜后5日平均跌4.10%。 资金流向方面，今日该股主力资金净流出7447.69万元，其中，特大单净流出5892.59万元，大单资金净 ...

资金流向方面，今日该股主力资金净流出2799.52万元，其中，特大单净流出2175.68万元，大单资金净 流出623.84万元。近5日主力资金净流出2799.52万元。 2025年10月28日公司发布的三季报数据显示，前三季度公司共实现营业收入2.99亿元，同比增长 2.74%，实现净利润3267.42万元，同比增长36.41%。 百花医药(600721)今日跌停，全天换手率0.86%，成交额3636.38万元。龙虎榜数据显示，营业部席位合 计净卖出1703.91万元。 上交所公开信息显示，当日该股因日跌幅偏离值达-10.02%上榜，营业部席位合计净卖出1703.91万元。 证券时报·数据宝统计显示，上榜的前五大买卖营业部合计成交2432.55万元，其中，买入成交额为 364.32万元，卖出成交额为2068.23万元，合计净卖出1703.91万元。 具体来看，今日上榜营业部中，第一大买入营业部为平安证券股份有限公司深圳龙华人民路证券营业 部，买入金额为110.64万元，第一大卖出营业部为兴业证券股份有限公司上海天钥桥路证券营业部，卖 出金额为991.80万元。 买/卖会员营业部名称买入金额(万元)卖出金额(万 ...

Group 1 - The stock of Baihua Pharmaceutical experienced a significant decline on January 7, closing at 11.02 yuan, with a trading halt observed [1] - The buying side showed a small inflow of funds, with the top buyer being Ping An Securities, which purchased 1.1064 million yuan [1] - The total buying amount from the top five buying seats was 3.6432 million yuan [1] Group 2 - The selling side exhibited a more pronounced outflow, with the main seller being Industrial Securities, which sold 9.918 million yuan [1] - The total selling amount from the top five selling seats reached 20.6823 million yuan, significantly higher than the total buying amount [1] - Notably, the selling activities were associated with funds linked to the so-called "Wenzhou Gang" [1]

Core Viewpoint - Baihua Pharmaceutical (600721) experienced a trading halt today, with a daily decline of 10.02% and a turnover rate of 0.86%, resulting in a transaction volume of 36.36 million yuan [2] Trading Activity - The stock was listed on the Shanghai Stock Exchange due to a daily price deviation of -10.02%, with a total net sell of 17.04 million yuan from brokerage seats [2] - The top five brokerage seats accounted for a total transaction volume of 24.33 million yuan, with a buying amount of 3.64 million yuan and a selling amount of 20.68 million yuan, leading to a net sell of 17.04 million yuan [2] - The largest buying brokerage was Ping An Securities, Shenzhen Longhua People's Road, with a purchase amount of 1.11 million yuan, while the largest selling brokerage was Industrial Securities, Shanghai Tianyao Bridge Road, with a selling amount of 9.92 million yuan [2] Capital Flow - The stock saw a net outflow of 27.99 million yuan in principal funds today, with a significant outflow of 21.76 million yuan from large orders and 6.24 million yuan from medium orders [2] - Over the past five days, the total net outflow of principal funds reached 27.99 million yuan [2] Financial Performance - According to the Q3 report released on October 28, 2025, the company achieved a total operating revenue of 299 million yuan in the first three quarters, representing a year-on-year growth of 2.74%, and a net profit of 32.67 million yuan, reflecting a year-on-year increase of 36.41% [2]

百花医药此前发布的《关于筹划控制权变更事项的停牌公告》《关于筹划控制权变更事项继续停牌 的公告》及上述最新公告均未对交易方进行披露。 由于公司控股股东、实际控制人与交易对方未就控制权变更相关重大事项达成一致意见，本着审慎 的原则，决定终止本次控制权变更事项。公司目前各项经营情况正常，终止筹划控制权变更事项不会对 公司经营业绩和财务状况产生重大不利影响。为维护投资者利益，根据相关规定，经公司向上海证券交 易所申请，公司股票于 2026 年 1 月 7 日（星期三）开市起复牌。 中国经济网北京1月7日讯 百花医药(600721.SH)今日复牌跌停，截至收盘报11.02元，跌幅9.97%。 该股停牌前的最后一个交易日（2025年12月26日）盘中最高涨9.00%。 百花医药昨日晚间披露关于终止筹划控制权变更事项暨复牌的公告。因公司控股股东、实际控制人 米在齐、米恩华、杨小玲正在筹划公司股份协议转让事宜，该事项可能导致公司控制权发生变更。鉴于 该事项正在洽谈当中，尚存在不确定性，为保证公平信息披露，维护投资者利益，避免造成公司股价异 常波动，经公司向上海证券交易所申请，公司股票自 2025 年 12 月 29 日（星 ...

百花医药(600721.SH)今日复牌一字板跌停，目前封单金额高达3.24元，现报11.2亿元，总市值42.38亿 元。消息上，百花医药昨日盘后公告，因公司控股股东、实际控制人与交易对方未就控制权变更相关重 大事项达成一致意见，决定终止本次控制权变更事项。业绩方面，2025年前三季度，百花医药营收为 2.986亿元，同比增长2.74%，净利润3267万元，同比增长36.41%。 ...

Policy Developments - The National Medical Products Administration (NMPA) aims for a drug inspection pass rate of over 99% by 2025, with 19,700 batches to be inspected, ensuring overall drug safety stability in the country [1] Drug and Device Approvals - Qianjin Pharmaceutical announced that it and its subsidiary received drug registration certificates for Dydrogesterone tablets, Baricitinib tablets (4mg, 2mg), and Dapagliflozin tablets (5mg, 10mg), enhancing its product pipeline for sustainable development [2] - Haizhi Pharmaceutical's subsidiary received acceptance for the listing application of HSK39297 tablets, intended for treating adults with paroxysmal nocturnal hemoglobinuria (PNH) who have not previously received complement inhibitors [3] - Xuantai Pharmaceutical obtained a drug registration certificate for injectable Isavuconazole, which is used to treat invasive aspergillosis and mucormycosis in adults [4] Capital Market Insights - Xiangyu Medical reported that as of the end of 2025, its brain-computer interface products have not achieved large-scale sales, with revenue contribution remaining minimal due to delays in bidding and sales processes [5] - Sanbo Brain Science clarified that it does not engage in the research, production, or sales of brain-computer interface products, and the revenue from neuro-regulation technology is negligible [6] - Weisi Medical stated that its new products in the brain-computer interface field are still in the early market cultivation stage, with limited revenue contribution [7] - Qiangna Technology, a "unicorn" in the brain-computer interface sector, completed approximately 2 billion RMB in financing, marking the second-largest financing in the field after Neuralink [8] - Baihua Pharmaceutical announced the termination of its control change plan due to a lack of consensus with the controlling shareholder, with stock resuming trading on January 7, 2026 [9] Industry Developments - Puluo Pharmaceutical signed a strategic cooperation framework agreement with Xi'an Xintong Pharmaceutical Research Co., Ltd. to collaborate on innovative drug research and outsourced production projects [10] - Yong'an Pharmaceutical plans to absorb and merge its wholly-owned subsidiary Hubei Ling'an Technology Co., Ltd., with recent financial data showing total assets of 180 million RMB and a net profit of -1.12 million RMB for the subsidiary [11] - Baiyang Pharmaceutical established a collaborative innovation laboratory with Capital Medical University Xuanwu Hospital to focus on cutting-edge medical research in neuroscience and thoracic surgery [12] - Insilico Medicine announced an $888 million collaboration with Servier for the development of anti-tumor drugs, with potential upfront payments and milestone payments involved [13] Public Sentiment Alerts - WuXi AppTec disclosed that shareholders controlled by the actual controller have cumulatively reduced their holdings by 59.6751 million shares, accounting for 2% of the total share capital, with the reduction completed on January 5, 2026 [14]

Summary of Key Points Core Viewpoint - Multiple shareholders from various companies are planning to reduce their stakes, indicating potential shifts in ownership and market dynamics [1]. Shareholder Reductions - **Shanwaishan**: Shareholders Yuanwaiyuan, Chongqing Dexiang, and Chongqing Derui plan to reduce a total of no more than 6.3747 million shares [1]. - **Oriental Zhongke**: Shareholder Dalian Jintou intends to reduce no more than 3% of its shares [1]. - **Mengke Pharmaceutical**: Shareholder Mengke Hong Kong plans to reduce no more than 3% of its shares [1]. - **Shengke Communication**: Shareholder National Integrated Circuit Industry Investment Fund plans to reduce no more than 3% of its shares [1]. - **Pioneer Electronics**: The controlling shareholder plans to reduce no more than 1% of its shares [1]. - **Heer Technology**: Chairman Liu Jianwei plans to reduce no more than 2% of his shares [1]. - **Sifang Jichuang**: The controlling shareholder and its concerted parties plan to reduce no more than 2% of their shares [1]. - **Yinbang Shares**: Shareholder Huaibei Public Utilities plans to reduce no more than 3% of its shares [1]. - **Fulaiwang**: The controlling shareholder plans to reduce no more than 2.9977% of its shares [1]. - **Thinking Control**: The company has terminated plans for a change in control and will resume trading on January 7 [1]. - **Baihua Pharmaceutical**: The company has also terminated plans for a change in control and will resume trading on January 7 [1].

Group 1 - The Ministry of Commerce announced that the "old-for-new" policy will drive consumer goods sales to reach 3.92 trillion yuan, benefiting 494 million consumers [3] - The policy will include support for the update of commercial facilities and energy-saving equipment, encouraging local governments to provide policy support for sorting center construction [3] - The "14th Five-Year Plan" aims to promote the construction of approximately 200 "waste-free cities" and increase the supply of high-quality green agricultural products [3] Group 2 - The People's Bank of China emphasized the importance of promoting high-quality economic development and reasonable price recovery in its monetary policy considerations [3] - The central bank plans to maintain ample liquidity and relatively loose social financing conditions to align monetary supply growth with economic growth and price level expectations [3] Group 3 - China Satcom issued a risk warning regarding its stock, which has increased by 108.64% since December 3, 2025, significantly outpacing the industry and market indices [5] - The company’s current price-to-earnings ratio stands at 704.09, far exceeding the industry average, indicating a potential risk of a significant price drop [5] Group 4 - Chipsource announced an investment in TianSui Chip Technology, acquiring control of ZhiDian Semiconductor, with a capital increase of 940 million yuan [6] - The company will hold a 40% stake in TianSui Chip Technology, becoming its largest shareholder [6] Group 5 - Aerospace Electronics reported a stock price increase of 123.23% since November 27, 2025, indicating a potential market overheating situation [7] - The stock's trading volume has been significant, raising concerns about the sustainability of its current price level [7] Group 6 - Keda Xunfei is collaborating with over 500 intelligent robot manufacturers, providing AI services based on its multi-modal perception and large model capabilities [7] - The company is positioned as a key player in the robotics industry, partnering with leading firms [7] Group 7 - Zhongtai Co. expects a net profit of 420 million to 480 million yuan for 2025, indicating a turnaround from losses [9] - Lier Chemical anticipates a net profit of 460 million to 500 million yuan, representing a year-on-year growth of 113.62% to 132.19% [9]